Ultragenyx Pharma - RARE Operating Margin

Ultragenyx Pharma - graphic logo of issuer RARE

Ultragenyx Pharmaceutical (RARE) relies on an impeccable reputation in treating rare pathologies and an ethical corporate culture that retains valuable scientists. At the core of its strategy are breakthrough gene therapy and mRNA methods designed to combat mutations neglected by medicine. The operating margin time series confirms the effectiveness of cost management, while the -64.10 metric reflects the current dynamics of profit from core operations.

Ultragenyx (RARE): Operating Profit Rate from 07/04/2022 to 11/20/2026

Analytical breakdowns and data insights for company Ultragenyx Pharmaceutical (RARE)

- share price and consensus valuation forecast:
Comprehensive company analysis:ultragenyx.com, RARE
Finished products of Ultragenyx Corp

This metric serves as a key filter during asset stress testing, allowing for an assessment of cost management efficiency before accounting for financial leverage and tax obligations. An analysis of the operating margin indicator demonstrates the share of profit from core operations in revenue, which for Ultragenyx Pharmaceutical (RARE) confirms a successful transition to drug commercialization and growth in profitability regardless of macroeconomic fluctuations.

Competitors of Ultragenyx Pharmaceutical

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Beam Tx (BEAM) - Operating Sales Margin|SRPT (Sarepta Therapeutics Inc) - Operating Sales Margin|TWST: Operating Profit Ratio|TXG (10xgenomics.com) - Operating Margin|NTLA (Intellia Therapeutics, Inc.) - Operating Profit Ratio|Operating Profitability Stoke Corp (STOK)|Profitability of Operations BioLife|Operating Margin WVE (Wave Life Sciences Ltd)|MAZE: Return on Sales by Operating Profit|Sionna Therapeutics, Inc. - Operating Margin|Operating Profit Rate PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Operating Sales Margin|QURE - Profitability of Operations|MGTX (MeiraGTx Corp) - Operating Margin|Operating Return on Sales REGENXBIO Inc. RGNX|Operating Profitability Solid Biosciences (SLDB)|Ocugen Corp - Return on Sales by Operating Profit|Operating Profitability Pacific Biosciences PACB|Operating Profit Ratio BNTC (Benitec)|Design Corp - Operating Margin|Rocket Pharmaceuticals - Operating Profit Ratio|Return on Sales by Operating Profit 4D Molecular Therapeutics, Inc.|Operating Return on Sales Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Operating Margin|Operating Return on Sales Editas EDIT|Operating Margin SLN|ProQR Therapeutics - Return on Sales by Operating Profit|Operating Margin CDXS (Codexis, Inc.)|SGMO: Return on Sales by Operating Profit|Nautilus Biotechnology - Operating Margin|Operating Profit Rate MGX (Metagenomi, Inc)|DTIL: Operating Margin|GBIO: Operating Profit Ratio|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability